William van Kampen, Xoran Chief Technology Officer and principal investigator on the project.

William van Kampen, Xoran Chief Technology Officer and principal investigator on the project. 


June 24, 2022 — Xoran Technologies announced they have begun work on Phase 2 of their mobile lung grant with the goal to confirm the safety and utility of a future thoracic point-of-care CT system in support of an FDA 510k submission. 

“It’s hard to overstate how transformative this technology would be for us in the ICU,” says Robert Dickson, MD, Associate Professor—Pulmonary & Critical Care Medicine, Associate Professor—Microbiology & Immunology, and a clinical collaborator, all at the University of Michigan. “Every day, we make clinical decisions based on chest X-rays, which are limited in what they can tell us about what is going on in the chest or abdomen. Our patients are often too sick to transport down to radiology, or they have a communicable disease like COVID-19 that we don’t want to spread around the hospital. A bedside scanner would have immediate impact in how we manage our sickest patients.” 

In 2021, Xoran Technologies was notified of a grant award from the National Heart, Lung, and Blood Institute (NHLBI) through the National Institutes of Health (NIH) to support the company’s research and development efforts for lung cone beam computed tomography (CT) imaging. Earlier this year, Xoran announced they completed Phase 1 of this grant. Just last month, Xoran submitted its 510k for TRON, an open-bore fluoroscopy CT for full-body point-of-care imaging. 

“We greatly appreciate the support from NHLBI as well as a fantastic collaboration with doctors at the University of Michigan,” states William van Kampen, Xoran’s Chief Technology Officer and principal investigator on the project. “This grant enables us to obtain valuable clinical feedback and accelerate our commercialization of this exciting technology and help bring imaging to patients who are in great need.” 

This project allows Xoran to optimize a point-of-care solution specifically for lung imaging. The combined Xoran and UofM teams aim to develop a highly deployable CT scanner intended for use in ICU, especially for patients with acute respiratory failure requiring mechanical ventilation. 

For more information: www.xorantech.com 


Related Content

News | Lung Imaging

April, 15, 2025 — Optellum has entered an agreement with Bristol Myers Squibb to leverage AI in early diagnosis and ...

Time April 17, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | SPECT Imaging

Feb. 5, 2025 — Serac Healthcare Ltd., a clinical radiopharmaceutical company developing an innovative molecular imaging ...

Time February 05, 2025
arrow
News | Computed Tomography (CT)

Dec. 3, 2024 — During RSNA '24, GE HealthCare announced the 510(k) submission to the U.S. Food and Drug Administration ...

Time December 18, 2024
arrow
News | SPECT Imaging

Dec. 2, 2024 — GE HealthCare has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing ...

Time December 05, 2024
arrow
News | Artificial Intelligence

Sept. 13, 2024 — Bayer Calantic Digital Solutions has announced the availability of a new eBook that addresses how ...

Time September 12, 2024
arrow
News | Computed Tomography (CT)

At the annual AHRA (American Healthcare Radiology Administrators) conference in Orlando, Florida, Bayer announced an ...

Time August 09, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
Subscribe Now